Pharmaceutical

Amphastar Pharmaceuticals to Present at the Barclays 26th Annual Global Healthcare Conference

RANCHO CUCAMONGA, CA / ACCESSWIRE / March 6, 2024 / Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) announced today that Bill Peters, CFO…

10 months ago

Intellipharmaceutics Announces Cease Trade Order

TORONTO, ON / ACCESSWIRE / March 6, 2024 / Intellipharmaceutics International Inc. (OTCQB:IPCIF)(TSX:IPCI) ("Intellipharmaceutics" or the "Company"), a pharmaceutical company…

10 months ago

KORU Medical Systems Signs a Clinical Supply Agreement for Phase 3 Trial with Leading Pharma Partner Using Custom Device for a Novel Subcutaneous Immunoglobulin

MAHWAH, N.J.--(BUSINESS WIRE)--KORU Medical Systems, Inc. (NASDAQ: KRMD) (“KORU Medical” or the “Company”), a leading medical technology company focused on…

10 months ago

Salix Pharmaceuticals Announces a Phase 2 Investigator-Initiated Study of RELISTOR(R) (methylnaltrexone bromide: MNTX) in Patients with Resectable Head and Neck Squamous Cell Carcinoma

LAVAL, QC / ACCESSWIRE / March 6, 2024 / Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC) and its gastroenterology business, Salix Pharmaceuticals,…

10 months ago

Serve You Rx Joins Forces With Mark Cuban Cost Plus Drug Company to Enhance Prescription Affordability for Members

Independent PBM Provides Clients With Flexible Ways to Boost Prescription AffordabilityMILWAUKEE, WI / ACCESSWIRE / March 5, 2024 / Serve…

10 months ago

Lexaria to Begin Diabetes and Weight Loss Animal Study WEIGHT-A24-1

Multiple DehydraTECH-GLP-1 and DehydraTECH-CBD formulations to be testedChronic dosing over a 12-week treatment periodWill assess weight loss and blood glucose…

10 months ago

New Survey Finds More Than Half of Past U.S. Colonoscopy Patients Wish They Had Known More Information About Colonoscopies Including Prep Medication Options and How To Prepare for the Procedure

Salix Pharmaceuticals Releases Findings from First Colonoscopy Awareness SurveyLAVAL, QC / ACCESSWIRE / March 5, 2024 / Bausch Health Companies…

10 months ago

FSD Pharma Presents Positive Results on First-In-Human Phase-1 study of Lucid-21-302 (Lucid-MS) at Americas Committee for Treatment and Research in Multiple Sclerosis (ACTRIMS) 2024 Forum

TORONTO, ON / ACCESSWIRE / March 5, 2024 / FSD Pharma Inc. (NASDAQ:HUGE)(CSE:HUGE)(FRA:0K9A) ("FSD Pharma" or the "Company"), a biopharmaceutical…

10 months ago

AIDS Clinical Trial Group Presents Results from Phase 1 Study of ModeX Trispecific Antibody for the Treatment and Prevention of HIV

• Study delivers first clinical safety and pharmacokinetic data as proof of concept for the use of multispecific antibodies in humans•…

10 months ago

Michael F. Roizen, MD to Increase Activities with Telomir Pharmaceuticals as Special Advisor on Age Reversal

Dr. Roizen to provide expertise on longevity and aging Research on aging involving Telomir’s lead product candidate focused on reversing age-related…

10 months ago